David H Margolin Selected Research

Alemtuzumab (Campath)

1/2021	Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.
11/2020	Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
10/2020	Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years.
1/2020	Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
1/2020	Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
10/2019	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.
1/2019	Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.
9/2017	Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
9/2017	Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
11/2016	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David H Margolin Research Topics

Disease

20	Relapsing-Remitting Multiple Sclerosis 01/2021 - 10/2008
13	Multiple Sclerosis 11/2020 - 10/2008
5	Infections 01/2021 - 10/2008
5	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2020 - 10/2008
2	Anti-Glomerular Basement Membrane Disease (Goodpasture's Syndrome) 01/2019 - 01/2013
1	Schizophrenia (Dementia Praecox) 01/2022
1	Psychotic Disorders (Schizoaffective Disorder) 01/2022
1	Parkinson Disease (Parkinson's Disease) 01/2022
1	Chronic Progressive Multiple Sclerosis 10/2020
1	Membranous Glomerulonephritis (Membranous Nephropathy) 01/2019
1	Atrophy 09/2017
1	Hypothyroidism 01/2014
1	Subacute Thyroiditis (Thyroiditis, De Quervain) 01/2014
1	Hyperthyroidism 01/2014
1	Papillary Carcinoma 11/2012
1	Pathologic Complete Response 12/2011
1	Hypogonadism (Hypergonadotropic Hypogonadism) 04/2002
1	Dementia (Dementias) 04/2002
1	Ataxia (Dyssynergia) 04/2002

Drug/Important Bio-Agent (IBA)

21	Alemtuzumab (Campath)FDA Link 01/2021 - 10/2008
14	Interferon beta-1a FDA Link 01/2021 - 10/2008
5	Monoclonal AntibodiesIBA 07/2015 - 10/2008
2	Inosine Triphosphate (ITP)IBA 01/2020 - 12/2011
2	InterferonsIBA 10/2016 - 04/2011
1	Antipsychotic Agents (Antipsychotics)IBA 01/2022
1	Serotonin (5 Hydroxytryptamine)IBA 01/2022
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Acyclovir (Aciclovir)FDA LinkGeneric 10/2019
1	Cytidine Diphosphate (CDP)IBA 01/2019
1	antiglomerular basement membrane antibodyIBA 01/2019
1	Interferon-betaIBA 11/2012
1	Glatiramer Acetate (Copaxone)FDA Link 11/2012
1	GonadotropinsIBA 04/2002
1	SteroidsIBA 04/2002

Therapy/Procedure

10	Therapeutics 01/2020 - 10/2008
1	Retreatment 10/2019
1	Off-Label Use 01/2019
1	Intravenous Infusions 07/2015